Gilead and Arcus share positive data from Phase 2 ARC-7 study of zimberelimab

Gilead Sciences (Nasdaq: GILD) and Arcus Biosciences (NYSE:RCUS) are touting positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO).

Patients in the arms who received the investigational Fc-silent anti-TIGIT monoclonal antibody domvanalimab had a reduction in risk of progression or death between 35% and 45%. They also had a doubling of median progression-free survival.

Patients in the study had a PD-L1 tumor proportion score (TPS) of 50% or greater without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations.

Patients in the domvanalimab received the drug with the investigational anti-PD1 monoclonal antibody zimberelimab (doublet arm) or were administered those two drugs in combination with the small-molecule, dual adenosine receptor antagonist etrumadenan…

Read more
  • 0